NewsBenzingaInMode、2026会計年度の調整後EPS見通しを1.29~1.34ドル、売上高見通しを3億6,500万~3億7,500万ドルと据え置き ― 市場予想はEPS1.30ドル、売上高3億7,032.8万ドル InMode、2026会計年度の調整後EPS見通しを1.29~1.34ドル、売上高見通しを3億6,500万~3億7,500万ドルと据え置き ― 市場予想はEPS1.30ドル、売上高3億7,032.8万ドル Benzinga 2026.11.11 12:01 (GMT+0) Open on Benzinga Other news Global-E Online Stock Is Falling Wednesday: What's Going On? Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $6 Stifel Maintains Buy on Ecolab, Raises Price Target to $356 Stifel Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $26 Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients
Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease
Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients